Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5KD99)

Drug Name

Narsoplimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
IgA nephropathy	MF8Y	Phase 3	[1]
Thrombotic microangiopathy	3B65	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mannan-binding lectin serine protease-2 (MASP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OMS721	DMK6QBZ	Atypical hemolytic uremic syndrome	3A10.Y	Phase 3	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mannan-binding lectin serine protease-2 (MASP2)	TTR01E9	MASP2_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03608033) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT02222545) A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies. U.S.National Institutes of Health.
3	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022 Aug 1;40(22):2447-2457.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)